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Abstract
Background: Cancer is responsible for elevated HIV-related morbidity and mortality. Research on HIV-infected
patients with concurrent cancer is rare in China. The purpose of our study was to investigate the prevalence and
risk factors associated with cancer among HIV-infected inpatients in Beijing, and to investigate the mortality and risk
factors among HIV-infected inpatients with cancer.
Methods: Hospital records from a total of 1946 HIV-infected patients were collected from the Beijing Ditan
Hospital. The data, from 2008 to 2013, were collected retrospectively. The cancer diagnoses included AIDS-defining
cancers (ADC) and non-AIDS defining cancers (NADC). Logistic regression was used to identify risk factors
predicting the concurrence of cancer with HIV. Mortality was examined using Kaplan-Meier estimates and Cox
proportional hazards models.
Results: 7.7 % (149 cases) of all HIV-infected inpatients had concurrent cancer at their first hospital admission; of
those, 33.6 % (50 cases) had ADCs, and 66.4 % (99 cases) had NADCs. The most prevalent NADCs were Hodgkin’s
lymphoma, gastrointestinal cancer, liver cancer, and lung cancer. Patients who did not accept antiretroviral therapy
(ART) were more likely to suffer from cancer [AOR = 2.07 (1.42–3.01), p = 0.001]. Kaplan-Meier curves indicated that
the survival probability of HIV-positive cancer patients was significantly lower than that of HIV-positive cancer-free
patients (log-rank test, p < 0.001). For patients diagnosed with cancer, the mortality was also higher among those
who did not receive ART [AHR = 2.19 (1.84–2.61), p < 0.001].
Conclusion: The prevalence of cancer concurrence among hospitalized HIV-infected patients was 7.7 %. Concurrent
cancer also increased mortality among HIV-infected patients. ART was protective against concurrent cancer as well
as mortality among HIV-infected cancer patients. These results highlight the importance of promoting cancer
screening and early ART initiation among HIV-infected patients.
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Background
People living with HIV/AIDS (PLWHA) are at higher
risk of developing concurrent cancer due to the impair-
ment of the immune system [1]. Cancer is in turn re-
sponsible for increased HIV-related morbidity and
mortality [2, 3]. Cancers can be categorized by their as-
sociations with HIV/AIDS as AIDS-defining cancers
(ADCs) and non-AIDS-defining cancers (NADCs) [4].
Generally, risk factors for developing cancer among
PLWHA include low CD4 cell count or late stage of
AIDS, co-infection with other viruses, cigarette smoking,
alcohol consumption, and advanced age [5].
Globally, the wide application of antiretroviral therapy
(ART), which has changed HIV/AIDS from a fatal dis-
ease to a chronic one, has contributed to a shift in can-
cer patterns among HIV-infected patients [6]. Evidence
reveals that risk of ADCs has been dropping among
HIV/AIDS patients since 1996 [6]. However, NADCs
burden among HIV/AIDS patients are still on the rise
[5–7] for reasons that remain unclear. In addition, al-
though ART has been reported to be effective in lower-
ing the risk of opportunistic infection and treating
cancer-related diseases [8–10], evidence for the efficacy
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of ART in preventing the development of concurrent
cancer among HIV-infected patients is lacking.
The mortality rate of ADCs has decreased while the
mortality rate of NADCs has increased in the ART era
[7, 11, 12]. While the former was always attributed to
the wider application of ART [13, 14], deaths due to
NADCs have been on the rise. Some studies attributed
the increasing mortality of NADCs to lifestyle factors
such as alcohol consumption and drug abuse [15], while
others considered older age and lower CD4 counts to be
the responsible factors [16].
In 2004, China started its free national ART program
and began to provide free ART medications as well as
related services to HIV-infected patients. The mortality
of Chinese AIDS patients subsequently experienced a
significant decline in the following decade [17]. However,
very limited information is available on concurrent can-
cer among HIV/AIDS patients in China. Some HIV-
infected patients were not identified until their CD4
counts decreased to less than 200 cells/mm3, after the
onset of AIDS [17–19]. Late identification of HIV infec-
tion and under-resourced healthcare settings, especially
in rural China, made concurrent cancer identification
difficult. As a result, the prevalence of cancer concur-
rence among PLWHA was underestimated.
This study, based on a 5-year retrospective cohort at
Beijing Ditan Hospital, focuses on the epidemiology of
cancer among PLWHA. Our hypothesis was that ART
was protective against concurrent cancer as well as
cancer-related mortality among HIV-infected patients.
We aimed to identify the risk factors associated with
concurrent cancer among PLWHA and risk factors asso-
ciated with mortality among PLWHA with cancer.
Methods
Study population
Beijing Ditan Hospital is one of largest specialized hospi-
tals providing healthcare services to HIV-infected pa-
tients in China. As Beijing Ditan Hospital is a
comprehensive, well-staffed, and well-equipped hospital
with a professional reputation, HIV-infected patients
from across China travel to the hospital to seek medical
services. Therefore, the sample from Beijing Ditan Hos-
pital is composed of a mix of HIV patients from all over
the country.
Data collection
Information on each patient was collected from his/her
hospital records. Permission was obtained from Beijing
Ditan Hospital for accessing the patient medical records.
The follow-up data within the observational period were
extracted from the national AIDS information system,
which compiles compulsory reports of HIV cases as well
as follow-up data every 6 months. Information collected
in this system included demography, updated health sta-
tus, CD4 counts, ART status, and survival status. The
national AIDS information system is not publicly avail-
able. For the study, we applied the permission of data
use for this study from National Center for AIDS/STD
Control and Prevention, which took responsibility of
managing the information system.
Sampling criteria
We included all HIV-infected inpatients older than 20
who were admitted to Beijing Ditan Hospital between
January 1, 2008 and December 31, 2013. Patients were
considered to be enrolled in the study from the time of
their first admission to Beijing Ditan Hospital until death
or the end of the study period on December 31, 2013.
Outpatient records were not included as the records did
not include all of the necessary information. The retro-
spective data collection was performed from May 1 to
June 30, 2014. The sampling framework for this study is
shown in Fig. 1. Data from the national AIDS informa-
tion system was linked to hospital data to determine
their time of HIV diagnosis, first CD4 count after HIV
diagnosis, subsequent CD4 record, the time of ART ini-
tiation and the death time.
Definition of the variables
HIV infection was defined as being laboratory-confirmed
using Western blot. As is widely accepted [20, 21], cancers
were categorized as ADCs (Kaposi’s sarcoma, KS; non-
Hodgkin’s lymphoma, NHL; and cervical cancer) or
NADCs (cancers of the lung, liver, kidney, anus, head and
neck, skin, Hodgkin’s lymphoma, etc.). Cancer was diag-
nosed by image examination and biomarker analysis and
further verified by biopsy. The time of first cancer diagno-
sis was not collected in this study.
Fig. 1 Framework of the study
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Statistical analysis
Patients with no record of death were censored at the end
of the study period on December 31, 2013. Continuous var-
iables were summarized using median and interquartile
range (IQR), and categorical variables were summarized
using frequencies and percentages. Cross-tabulations with
χ2 or Fisher’s exact tests were performed to relate variables
of interest. A multivariate logistic regression model was
used to identify factors of concurrent cancer at the first
hospitalization. Kaplan-Meier curves were used to estimate
the survival function during the study period. A multivari-
ate Cox proportional hazards model was used to identify
the prognostic risk of death among patients with cancer.
The start time of Cox analysis was first HIV diagnosis. Up-
dated CD4 counts and ART status were modelled as time-
dependent covariates. CD4 count was kept as continuous
variable. A p-value of less than 0.05 was considered signifi-
cant in the final reduced multivariate model. Patients with
missing data were kept in the table and classified in the ‘un-
known’ group. Data was managed and analysed using the
SAS 9.2 statistical software.
Ethical considerations
This study was reviewed and approved by the Institu-
tional Review Board of the National Center for AIDS/
STD Control and Prevention of the Chinese Center for
Disease Control and Prevention. All participants signed
the routine informed consent form when they were ad-
mitted to the hospital and no further informed consent
was required. Patient information was de-identified for
data analysis.
Results
From January 1, 2008 to December 31, 2013, a total of
2111 hospitalized HIV-infected patients’ records were
incorporated into the study from their admissions to the
hospital. 165 cases (18 foreigners, 35 below the age re-
quirement, 112 without sufficient information) were ex-
cluded based on our inclusion criteria. Ultimately, 1946
patients were enrolled in this study; their records were
analysed with a total of 59,016 patient-months of follow-
up.
Characteristics of the patients
The baseline characteristics of ADC-concurrent, NADC-
concurrent, and cancer-free HIV-infected inpatients are
summarized in Table 1. 149 out of 1946 HIV-infected in-
patients were diagnosed with concurrent cancer, ac-
counting for 7.7 % of the study population. Among
them, 33.6 % (50 patients) were diagnosed with ADCs,
and 66.4 % (99 patients) were diagnosed with NADCs.
The distribution of ADCs, as shown in Fig. 2, was 46 %
NHL, 38 % KS, and 16 % cervical cancer. The most
prevalent NADCs were Hodgkin’s lymphoma (27 %),
gastrointestinal cancer (16 %), liver cancer (14 %), and
lung cancer (13 %).
There were nearly four times as many male patients
(1547) as female patients (399), but 10 % of female HIV
patients were diagnosed with cancer compared to 7 % of
male HIV patients in the study (p < 0.05). The median
age of HIV-infected patients without cancer was 37 years
old, which was significantly younger than that of HIV-
infected patients with cancer, at 44 years old (p < 0.001).
52.3 % of HIV-infected cancer patients initiated ART be-
fore admission at Beijing Ditan Hospital compared to
67.1 % of cancer-free patients (p = 0.004).
From the logistic regression model (Table 2), we iden-
tified ART status as a strong independent factor of can-
cer status among HIV-infected patients. Patients not on
ART were more likely to have cancer than patients who
were on ART [AOR = 2.07 (1.42–3.01), p = 0.001]. Ad-
vanced age is also associated with a slightly elevated risk
of developing cancer [AOR = 1.05 (1.03–1.06), p = 0.001],
while gender, route of HIV contraction, and CD4 cell
count at HIV diagnosis were not found to be predictive
of cancer status.
Patients without cancer had significantly higher sur-
vival rates over the follow-up period than patients with
ADCs or NADCs (log-rank test p < 0.001) (Fig. 3). A
multivariate Cox proportional hazards analysis (Table 3)
showed that patients with cancer who were not on ART
were at higher risk for death [AHR = 2.19 (1.84–2.61), p
< 0.001]. Time updating CD4 cell counts (from HIV
diagnosis to the endpoint of this study) and advanced
age did not affect mortality.
Discussion
Research on HIV-infected patients with concurrent can-
cer is lacking in China [22]. The purpose of this study
was to investigate the prevalence of cancer in HIV-
infected inpatients and to identify the risk factors associ-
ated with cancer among PLWHA and with mortality
among PLWHA with cancer.
Related factors for developing cancer among the HIV-
infected population include low CD4 cell count, route of
HIV contraction, co-infection with other viruses, late
stage of AIDS, cigarette smoking, alcohol consumption,
and advanced age [5]. The finding of advanced age as an
independent predictor of developing cancer is consistent
with previous studies [7]. In our study, patients with
cancer were on average 7 years older than those without
cancer (44 years versus 37 years, p = 0.026), suggesting
that it may be meaningful to advocate regular cancer
screening and care among older HIV patients in China.
The capacity for cancer screening and diagnosis largely
depends on techniques such as biomarker analysis, CT
and MRI scanning, endoscopy, and biopsy [23]. These
methods are available at major hospitals, but many HIV
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patients in rural China may miss the opportunity to be
screened for cancer due to the high cost burden or the
inaccessibility of medical facilities or service providers.
The prevalence, of cancer among patients enrolled in
our study was 7.7 % (149/1946). Data from the national
registry indicated that the crude incidence rate of cancer
in 2011 was 235/100,000 and that cancers of the lung,
female breast, gastrointestinal tract, liver, and cervix
were the most common malignancies in China [24]. In
our HIV-positive population, the most prevalent NADCs
were Hodgkin’s lymphoma, gastrointestinal cancer, liver
cancer, and lung cancer, different from the national
pattern.
Previous research in developed countries showed the
decrease of the incidences of ADCs and NADCs in the
post-ART era [25]. As China’s national ART program
began later than those of most developed countries and
some HIV-infected patients were first identified at a late
stage with low CD4 counts [19], it is reasonable that
China still experiences HIV-related cancer epidemics in
the ART era [26]. It is therefore important to initiate
surveillance to track changes in the incidences of ADCs
and NADCs.
Effective ART was found to reduce some of the excess
risk of developing cancer among HIV patients [27]. The
ART rate among HIV patients diagnosed with cancer
was lower than among cancer-free patients (52.3 % ver-
sus 67.1 %, p = 0.004). Patients without ART were more
likely to get cancer than patients who accepted ART
[2.07 (1.42–3.01), p = 0.001]. This result indicated that
Table 1 Baseline clinical characteristics classified by cancer status among HIV-infected inpatients at Beijing Ditan Hospital, January 1,
2008 – December 31, 2013
Characteristics Cancer-Free Cancer p-value*
N (%) N (%)
All All ADCs NADCs
Total 1797 149 50 99
Gender 0.045
Female 359 (20.0) 40 (26.8) 15 (30.0) 25 (25.3)
Male 1438 (80.0) 109 (73.2) 35 (70.0) 74 (74.7)
Age (years)
Median (IQR) 37 (30–45) 44 (37–53) 50 (39–57) 42 (36–49) 0.026
Age group 0.002
21–30 466 (25.9) 14 (9.4) 1 (2.0) 13 (15.4)
31–40 621 (34.6) 48 (32.2) 14 (28.0) 34 (34.3)
41–50 455 (25.3) 37 (24.8) 8 (16.0) 29 (29.3)
51–60 171 (9.5) 32 (21.5) 16 (32.0) 16 (16.2)
≥ 61 84 (4.7) 18 (12.1) 11 (22.0) 7 (7.1)
HIV transmission mode 0.085
Men who have sex with men 635 (35.3) 35 (23.5) 6 (12.0) 29 (29.3)
Injection drug use 81 (4.5) 2 (1.3) 0 (0.0) 2 (2.0)
Heterosexual contact 800 (44.5) 83 (55.7) 31 (62.0) 52 (52.5)
Blood transmission 224 (12.5) 24 (16.1) 12 (24.0) 12 (12.1)
Unknown 57 (3.2) 5 (3.4) 1 (2.0) 4 (4.0)
Median days from HIV diagnosis to the first hospital admission (IQR) 111 (27–663) 215 (49–760) 350 (58–847) 140 (36–402) 0.015
Median first CD4 cell count after HIV diagnosis (IQR) (cells/μl) 131 (36–265) 127 (51–369) 146 (85–402) 91 (20–255) 0.213
0–200 997 (55.5) 79 (53.0) 26 (56.0) 53 (51.5)
201–350 422 (23.5) 29 (19.5) 10 (20.0) 19 (19.2)
351–500 245 (13.6) 27 (18.1) 8 (16.0) 19 (19.2)
> 500 133 (7.4) 14 (9.4) 6 (12.0) 8 (8.1)
Median CD4 cell count at the first hospital admission (IQR) (cells/μl) 289 (135–441) 265 (115–374) 297 (201–396) 240 (95–351) 0.381
ART initiation before the first hospital admission 1206 (67.1) 78 (52.3) 29 (58.0) 49 (49.5) 0.004
The CD4 cell count at ART initiation 147 (60–273) 137 (66–265) 160 (90–297) 102 (36–228) 0.067
*p-value for comparing of cancer-free versus cancer group
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treatment could be beneficial in reducing the risk of can-
cer among HIV-infected patients. Additionally, reasons
why patients who were not on ART even they were in
the serious progression should be considered. Being very
sick and near death reduced the likelihood that ART was
prescribed by their physician.
Mortality rates in both the cancer-concurrent
group as well as the cancer-free group were rela-
tively high, in part because our study population was
drawn from hospital admissions who were more
likely to have advanced disease progression. Our
finding that HIV-infected patients with cancer who
received ART were less likely to experience prema-
ture death is encouraging. A large-scale and long-
term cohort study in the U.S. found that overall
cancer-related mortality among PLWHA experienced
a major drop (from 302 to 29 per 1000 patients) be-
tween 1980 and 2006 [28]. Another U.S. cohort
study reported that mortality rates among HIV pa-
tients with cancer who received ART were much
lower than among HIV patients who did not, while
the time of ART initiation, before or after cancer
diagnosis, did not make a significant difference [3].
The Johns Hopkins AIDS Clinic cohort discovered
Table 2 Risk factors associated with concurrent cancer as calculated using logistic regression modeling among 1946 HIV-infected in-
patients at Beijing Ditan Hospital, January 1, 2008 – December 31, 2013




Male 0.68 (0.47–0.99) 0.042 0.68 (0.45–1.05) 0.422
Age group every 10-year increase 1.05 (1.03–1.06) 0.011 1.05 (1.03–1.06) 0.001
HIV transmission mode
Men who have sex with men 1.00 1.00
Injection drug use 0.45 (0.11–1.90) 0.156 0.37 (0.09–1.61) 0.085
Heterosexual contact 1.88 (1.25–2.83) 0.037 1.42 (0.84–1.82) 0.524
Blood transmission 1.94 (1.13–3.34) 0.041 1.07 (0.86–1.32) 0.554
Unknown 1.59 (0.60–4.22) 0.263 0.89 (0.32–2.54) 0.734
First CD4 cell count after HIV diagnosis (cells/μl)
0–200 1.00 1.00
201–350 0.87 (0.56–1.35) 0.533 1.08 (0.67–1.75) 0.745
351–500 0.86 (0.55–1.35) 0.514 1.02 (0.63–1.64) 0.950
> 500 0.57 (0.32–1.02) 0.057 0.71 (0.39–1.30) 0.263
ART initiation before the first hospital admission
Yes 1.00 1.00
No 1.86 (1.33–2.60) 0.01 2.07 (1.42–3.01) 0.001
OR odds ratio, CI confidence interval
Fig. 2 Distribution of cancers among HIV-infected inpatients with ADCs (A) and NADCs (B) at Beijing Ditan Hospital, January 1, 2008 – December 31, 2013
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no difference in mortality rates in ADCs and
NADCs among patients who received ART [29].
Limitations
Our study has a few limitations. The sample from
Beijing Ditan Hospital could be biased because it is a re-
ferral center for infection disease treatment. HIV-
infected patients admitted by Beijing Ditan Hospital
came from all over China, but the study population can-
not be considered a random sample as only those
who had relatively severe complications and who
could afford the medical expenses would come to this
hospital. As a result, selection bias may have oc-
curred, leading to the overestimation of the preva-
lence of concurrent cancer among HIV-infected
patients.
There was another major weakness of this study.
The time of first cancer diagnosis was not collected
in this study. Patients were assessed concurrent can-
cer when they were firstly hospitalized in our study
facility, Beijing Ditan hospital. We could not accur-
ately describe the occurrence of cancer.
Due to the nature of the retrospective study, it was not
possible for us to collect data on as many clinical vari-
ables as may have been needed for the study, such as
viral load. Therefore, there exists the possibility of re-
sidual confounding due to data insufficiency. For ex-
ample, the regression models did not include covariates
such as alcohol dependence and co-infection with other
viruses as in other studies, as they were not available in
all of our routine clinical data.
Conclusion
The concurrence of cancers among HIV-infected pa-
tients was 7.7 % in inpatients in our study hospital. Can-
cers increased mortality rates among HIV-infected
patients, but ART was effective both in reducing the risk
of cancer development among HIV-infected patients and
Table 3 Risk factors associated with mortality as calculated using Cox proportional hazards models among 149 inpatients with












Total 42 (28.2) 5355 0.78 – – – –
Gender
Female 13 (32.5) 2012 0.65 1.00 1.00
Male 29 (26.6) 3343 0.87 1.30 (0.67–2.53) 0.071 0.94 (0.41–2.13) 0.826
Age (every 10-year increase) 42 (28.2) 5355 0.78 1.02 (1.00–1.05) 0.923 1.02 (0.99–1.05) 0.912
HIV transmission mode
Men who have sex with men 8 (22.9) 1029 0.78 1.00 1.00
Injection drug use 0 (0.0) 110 0.00 – – – –
Heterosexual contact 23 (27.7) 2468 0.93 1.17 (0.52–2.63) 0.227 1.27 (0.44–3.66) 0.363
Blood transmission 9 (37.5) 1601 0.56 0.58 (0.21–1.62) 0.189 0.78 (0.23–2.67) 0.314
Unknown 2 (40.0) 146 1.37 1.85 (0.39–8.76) 0.456 6.71 (0.67–66.89) 0.532
CD4 cell counta
(per cell/μl increase)
42 (28.2) 5355 0.78 0.99 (0.99–0.99) <0.001 1.01 (0.99–1.02) 0.343
No ART initiationa 42 (28.2) 5355 0.78 2.52 (2.22–2.86) <0.001 2.19 (1.84–2.61) <0.001
Classification of cancer
NADC 23 (23.2) 3151 0.73 1.00 1.00
ADC 19 (38.0) 2204 0.86 1.12 (0.61–2.08) 0.121 0.86 (0.38–1.93) 0.082
HR hazard ratio, CI confidence interval
aVariables were modelled as time-dependent covariates
Fig. 3 Kaplan-Meier survival curves for HIV-infected inpatients
stratified by cancer type at Beijing Ditan Hospital, January 1, 2008 –
December 31, 2013
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in reducing the risk of cancer-related mortality. It is
therefore important to increase cancer screening and to
promote early initiation of ART among HIV-infected
patients.
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